Introduction

This patent delves into the detailed examination of the Akkermansia muciniphila Akk007, a probiotic with significant immunomodulatory properties. The strain has shown promise in enhancing immune function and is proposed for various applications in health supplements and functional foods.

Characteristics:

Akkermansia muciniphila Akk007 is identified for its ability to colonize the human gut, where it plays a critical role in maintaining the integrity of the mucosal barrier.

The strain has demonstrated an exceptional capacity to enhance the host's immune response.

It can modulate the gut microbiota, favorably influencing metabolic processes and offering protection against various pathogens.

Applications

1. Immune Enhancement:

The patent highlights the strain's ability to modulate immune responses, making it an effective component in supplements designed to boost immunity.

Clinical trials and in vivo studies have shown that Akkermansia muciniphila Akk007 can increase the production of anti-inflammatory cytokines and enhance the activity of immune cells.

2. Use in Health Products:

Akkermansia muciniphila Akk007 is utilized in the formulation of various health supplements aimed at improving gut health and immunity.

The strain can be incorporated into dairy products, capsules, and tablets, ensuring the delivery of viable cells to the gut.

The potential for inclusion in functional foods is also explored, where it could be combined with prebiotics to maximize its probiotic effects.

Experimental Evidence

· Animal Studies:

Experiments conducted on mice have demonstrated significant improvements in gut health and immune response upon administration of the strain.

The studies revealed an increase in the number of beneficial gut bacteria, along with a reduction in inflammation markers.

· Human Trials:

Preliminary human trials indicate that Akkermansia muciniphila Akk007 can improve the gut microbial balance, which is linked to better overall health and enhanced immunity.

Potential Health Benefits

· Gut Health:

Promotes a healthy balance of gut microbiota.

Enhances mucosal barrier function, protecting against gastrointestinal disorders.

· Metabolic Health:

Supports metabolic processes, potentially aiding in weight management and the prevention of metabolic syndrome.

· Immune System Support:

Enhances the body's natural defenses against pathogens.

Modulates the immune system, reducing the risk of chronic inflammatory diseases.

Commercialization and Product Development

· Market Potential:

With increasing consumer awareness of gut health and immunity, Akkermansia muciniphila Akk007 has significant market potential in the functional foods and dietary supplements sectors.

The strain's unique properties position it as a valuable ingredient in the development of next-generation probiotic products.

· Product Formats:

The strain can be formulated into various product types, including probiotic capsules, sachets, yogurt, and other dairy products.

Its stability in different formulations ensures its viability and efficacy upon consumption.

Conclusion

The patented strain Akkermansia muciniphila Akk007 presents a promising addition to the probiotic market, particularly for its immune-enhancing properties. The strain's application in health products offers potential benefits in gut health, metabolic health, and immune support. As research continues, Akk007 may pave the way for innovative probiotic solutions that meet the growing demand for functional health products.